Stryker’s Model Drives Best-in-Class Performance

Stryker reported 3Q23 orthopedic sales of $2,446.8 million, +7.9% compared to the third quarter of 2022. For the first nine months of 2023, the company generated $7,437.1 million in orthopedic sales, representing 9.5% growth year-over-year.

Stryker opened its earnings call by addressing GLP-1 weight loss drugs. The company expects no...

document icon

You’ve reached your limit.

We’re glad you’re finding value in our content — and we’d love for you to keep going.

Subscribe now for unlimited access to orthopedic business intelligence.

ME

Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.



Contact Us

0